| Active substance |
CJC 1295 |
| Also known as |
DAC:GRF, Drug Affinity Complex: Growth Hormone Releasing Factor |
| Blood pressure |
No significant impact |
| Category |
Peptides |
| Chemical name |
L-Tyrosyl-D-alanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-valyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-alpha-glutamyl-L-valyl-L-valyl-L-tryptophyl-L-alphaglycyl-L-alphaglycyl-L-alphaglycyl-L-lysyl-L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-alphaglycyl-L-alphaglycyl-L-lysyl-L-alphaglycyl-L-histidyl-L-leucyl-L-isoleucyl-L-alphaglycyl-L-lysyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-valyl-L-alpha-glutamyl-L-arginyl-L-arginyl-L-leucyl |
| Dosage |
2 Mg |
| Dosage (medical) |
Typically 1-2 mg once or twice a week |
| Dosage (sports) |
1-2 mg two times a week |
| Dosage Unit |
Ml |
| ean13 |
1392806356603 |
| Effects |
Increased muscle growth, enhanced fat loss, improved skin elasticity, strengthened immune system |
| FORM |
Injection |
| Formula |
C152H252N44O42 |
| Half-life |
Approximately 6-8 days |
| Hepatotoxicity |
None reported |
| Lab Test |
Growth Hormone levels |
| Main action |
Increases plasma levels of growth hormone |
| Milliliter Size |
4 Ml |
| Reference |
SMCTRO40 |
| Side effects |
Irritation at injection site, water retention, tingling sensations, occasional dizziness |
| Storage conditions |
Should be refrigerated at 2-8 degrees Celsius, avoid freezing |
| Substance class |
Peptide hormone |
| Trade name |
Not available under a specific trade name |
| Use in sports |
Used to enhance performance and accelerate recovery |
| Water Retention |
Moderate |
| Packing |
Vial |
